Kiran Majumdar-Shaw, CEO of Biocon has to make to product launch, pricing, channel, and communications mix decisions related to the introduction of the BioMAb, a new cancer drug in India.

Kiran Majumdar-Shaw, CEO of Biocon has to make to product launch, pricing, channel, and communications mix decisions related to the introduction of the BioMAb, a new cancer drug in India.
«Hide

from
Sunil Gupta,
The Narayandas
Source: Harvard Business School
15 pages.
Publication Date: Aug 28, 2007. Prod #: 508026-PDF-ENG
Biocon: Launching a New Cancer Drug in India HBR case solution